RENO, NV, Oct. 12 /PRNewswire-FirstCall/ - ChromoCure, Inc. (PINKSHEETS: KKUR) today announced its has executed a Joint Venture Agreement with Sophora Diagnostic Lab, Inc., a profitable New York based cancer pathology lab (“Sophora”).
Under the Terms, Sophora will join ChromoCure’s pathology lab network and utilize ChromoCure’s cancer detection systems as part of its diagnostic operations.
Sophora will market its enhanced diagnostic services to area labs. ChromoCure and Sophora will divide revenues derived from the system equally.
Sophora is ChromoCure’s first and flagship installation for its cancer detection system, continuing designs and therapeutic technologies.
Installation, training, and system activation is anticipated to begin immediately. Additional installations of the Company’s technology are planned as part of ChromoCure’s lab network revenue and growth plan.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company’s systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company’s technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
CONTACT: Investor Relations: Contact: ChromoCure, Inc., info@chromocure.com, Tel (775) 636-6548
SOURCE ChromoCure, Inc.
CONTACT: Investor Relations: Contact: ChromoCure, Inc.,
info@chromocure.com, Tel (775) 636-6548
